Neogenomics
Open
$11.16
Prev. Close
$11.18
High
$11.17
Low
$11.12
Market Snapshot
$1.45B
-14.6
-0.62
$660.57M
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,500 full-time employees. The company went IPO on 2012-12-10. The firm offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. The company operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,500 full-time employees. The company went IPO on 2012-12-10. The firm offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. The company operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
Recently from Cashu
NeoGenomics Projects Strong Revenue Growth in Oncology Testing Market for Fiscal Year 2026
NeoGenomics Inc (Ticker: NEO) is experiencing notable progress in its oncology testing business, as indicated by a recent revenue guidance increase for fiscal year 2026. The company adjusts its revenu…
NeoGenomics Enhances Oncology Testing with Epic Aura Integration for Better Patient Outcomes
Earlier this week, NeoGenomics, Inc. announced a significant advancement in its oncology testing capabilities by integrating its portfolio into the Epic Aura platform. Advancing Oncology Testing throu…
NEO Wins Global Innovation Award, Transforming New-Construction Real Estate Practices
NEO’s Innovation Reshapes New-Construction Real Estate Dynamics NEO (New Estate Only), a leader in global listing services for new construction real estate, receives the Global Innovation Gold Award f…
NEO Wins Global Innovation Gold Award for New-Build Real Estate Excellence
NEO Revolutionizes New-Build Real Estate with Innovation Award Win In a landmark development for the new-construction real estate sector, NEO (New Estate Only) has been honored with the Global Innovat…